Syndecan-4 levels in bronchoalveolar lavage fluid and serum in non-small cell lung cancer

  • Asrul Abdul Azis Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
  • Arif Santoso Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
  • Irawaty Djaharuddin Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
  • Harun Iskandar Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
  • Muhammad Ilyas Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
  • Nurjannah Lihawa Department of Pulmonology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia; Wahidin Sudirohusodo Hospital, Makassar, Indonesia; Universitas Hasanuddin Hospital, Makassar, Indonesia
DOI: https://doi.org/10.13181/mji.oa.247264
Keywords: lung cancer, non-small cell lung cancer, syndecan-4
Abstract viewed: 57 times
PDF downloaded: 24 times
HTML downloaded: 1 times
EPUB downloaded: 3 times

Abstract

BACKGROUND Lung cancer has the highest cancer-related mortality rate worldwide. Research has been conducted to improve early detection and markers of predictive value but only focused on the expression of syndecan-4 (SDC4) in serum. Studies in bronchoalveolar lavage (BAL) fluids of non-small cell lung cancer (NSCLC) patients are still limited. This study aimed to evaluate the clinical value of SDC4 in serum and BAL in NSCLC patients.

METHODS Blood serum and BAL fluids were obtained from 44 patients with NSCLC and 41 non-cancer patients as the control. The level of SDC4 was measured. The relationships between SDC4 and clinicopathologic factors were also analyzed.

RESULTS Serum SDC4 levels in NSCLC patients were significantly lower than the control group (p = 0.002). Furthermore, the disease stages and serum SDC4 levels had a negative correlation, which was lower in the advanced stage (IIIb/IV) than in the initial stage (I/II/IIIa) (p = 0.517). The same results were obtained from BAL fluids SDC4 levels, which were significantly lower in the advanced stage (IIIb/IV) than in the early stage (I/II/IIIa) (p = 0.007).

CONCLUSIONS Serum SDC4 levels in NSCLC patients were lower than those of non-cancer patients. They also performed different results in disease stages. SDC4 could be a helpful biomarker in NSCLC.

Downloads

Download data is not yet available.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209−49. https://doi.org/10.3322/caac.21660

  2. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and molecular classification of lung cancer. Cancer Treat Res. 2016;170:25−46. https://doi.org/10.1007/978-3-319-40389-2_2

  3. Tsoyi K, Osorio JC, Chu SG, Fernandez IE, De Frias SP, Sholl L, et al. Lung adenocarcinoma syndecan-2 potentiates cell invasiveness. Am J Respir Cell Mol Biol. 2019;60(6):659−66. https://doi.org/10.1165/rcmb.2018-0118OC

  4. Carvalho AS, Moraes MC, Hyun Na C, Fierro-Monti I, Henriques A, Zahedi S, et al. Is the proteome of bronchoalveolar lavage extracellular vesicles a marker of advanced lung cancer? Cancers (Basel). 2020;12(11):3450. https://doi.org/10.3390/cancers12113450

  5. Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13−29. https://doi.org/10.1016/j.hoc.2016.08.006

  6. Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-based lung cancer screening: a systematic review. Lung Cancer. 2020;147:154−86. https://doi.org/10.1016/j.lungcan.2020.07.007

  7. Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463−73. https://doi.org/10.1016/j.mcna.2018.12.006

  8. Toba-Ichihashi Y, Yamaoka T, Ohmori T, Ohba M. Up-regulation of syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells. Biochem Biophys Rep. 2016;5:1-7. https://doi.org/10.1016/j.bbrep.2015.11.021

  9. Onyeisi JOS, Lopes CC, Götte M. Syndecan-4 as a pathogenesis factor and therapeutic target in cancer. Biomolecules. 2021;11(4):503. https://doi.org/10.3390/biom11040503

  10. Güden M, Karaman ST, Basat O. Evaluation of the relationship between the level of addiction and exhaled carbon monoxide levels with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in smokers. Tob Induc Dis. 2022;20:52. https://doi.org/10.18332/tid/149227

  11. Supriyanto DA, Damayanti T. Correlation of smoking habit and level of nicotine dependence in university students. Respir Sci. 2023;3(2):94-102. https://doi.org/10.36497/respirsci.v3i2.54

  12. Masturoh I, Anggita TN. Rekam Medis dan Informasi Kesehatan (RMIK) Metodologi Penelitian Kesehatan. 1st ed. Jakarta: Tim P2M2; 2018.

  13. Keller-Pinter A, Gyulai-Nagy S, Becsky D, Dux L, Rovo L. Syndecan-4 in tumor cell motility. Cancers (Basel). 2021;13(13):3322. https://doi.org/10.3390/cancers13133322

  14. Choi Y, Yun JH, Yoo J, Lee I, Kim H, Son HN, et al. New structural insight of c-terminal region of syntenin-1, enhancing the molecular dimerization and inhibitory function related on syndecan-4 signaling. Sci Rep. 2016;6:36818. https://doi.org/10.1038/srep36818

  15. El Ghazal R, Yin X, Johns SC, Swanson L, Macal M, Ghosh P, et al. Glycan sulfation modulates dendritic cell biology and tumor growth. Neoplasia. 2016;18(5):294−306. https://doi.org/10.1016/j.neo.2016.04.004

  16. Zhu Z, Ling X, Zhou H, Xie J. Syndecan-4 is the key proteoglycan involved in mediating sepsis-associated lung injury. Heliyon. 2023;9(8):e18600. https://doi.org/10.1016/j.heliyon.2023.e18600

  17. Afratis NA, Nikitovic D, Multhaupt HA, Theocharis AD, Couchman JR, Karamanos NK. Syndecans - key regulators of cell signaling and biological functions. FEBS J. 2017;284(1):27−41. https://doi.org/10.1111/febs.13940

  18. Gopal S. Syndecans in inflammation at a glance. Front Immunol. 2020;11:227. https://doi.org/10.3389/fimmu.2020.00227

  19. Jechorek D, Haeusler-Pliske I, Meyer F, Roessner A. Diagnostic value of syndecan-4 protein expression in colorectal cancer. Pathol Res Pract. 2021;222:153431. https://doi.org/10.1016/j.prp.2021.153431

  20. Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD, Karamanos NK. Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol. 2014;4:4. https://doi.org/10.3389/fonc.2014.00004

  21. Onyeisi JOS, Ferreira BZ, Nader HB, Lopes CC. Heparan sulfate proteoglycans as targets for cancer therapy: a review. Cancer Biol Ther. 2020;21(12):1087−94. https://doi.org/10.1080/15384047.2020.1838034

  22. Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, et al. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest. 2014;124(7):3016-31. https://doi.org/10.1172/JCI74270

  23. Liao WC, Yen HR, Chen CH, Chu YH, Song YC, Tseng TJ, et al. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. Am J Cancer Res. 2021;11(3):812−26.

  24. Lambert J, Makin K, Akbareian S, Johnson R, Alghamdi AA, Robinson SD, et al. ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis. J Cell Sci. 2020;133(7):jcs235762. https://doi.org/10.1242/jcs.235762

  25. Tanino Y, Wang X, Nikaido T, Misa K, Sato Y, Togawa R, et al. Syndecan-4 inhibits the development of pulmonary fibrosis by attenuating TGF-β signaling. Int J Mol Sci. 2019;20(20):4989. https://doi.org/10.3390/ijms20204989

Published
2024-07-24
How to Cite
1.
Abdul Azis A, Santoso A, Djaharuddin I, Iskandar H, Ilyas M, Lihawa N. Syndecan-4 levels in bronchoalveolar lavage fluid and serum in non-small cell lung cancer. Med J Indones [Internet]. 2024Jul.24 [cited 2024Jul.27];33(2):88-2. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/7264
Issue
Vol. 33 No. 2 (2024): June
Section
Clinical Research

Copyright (c) 2024 Asrul Abdul Azis, Arif Santoso, Irawaty Djaharuddin, Harun Iskandar, Muhammad Ilyas, Nurjannah Lihawa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.